Lisa Alderson has been helping to build genetic testing companies for a while.  In 2016 she co-founded her own company, Genome Medical, a tele-genomics firm to help patients and providers understand genetic testing results.

Anyone in the genetic testing industry will know that Genome Medical’s offering addresses a burning need.   As Lisa remarks in today’s show, genetics is complicated. 

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Lisa Alderson on Her Telegenetics Firm, Genome Medical, Also Speaks to the DTC Downturn

Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine. 

www.mendelspod.com

Tech News

Technology

Natural Sciences

Science & Medicine

Social Sciences

Medicine

News

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

A  new spatial biology company is promising to shake up the field. Last month, Curio Bioscience launched a new technology to early access customers that provides transcriptomic spatial data without the need to b…

Is this New Tech a Game Changer for Spatial Biology?

John Cumbers is back on the show to preview the annual SynBioBeta, the leading global conference for the synthetic biology crowd. This year’s show includes 18 tracks on AI, space, longevity, and DNA synthesis. Speakers will include Stephen Wolfram and Stephen Quake, who will discuss large language models and biology. While 2024 saw a total investment of over $6 billion (not as high as the pandemic year of 2021), John says the new technologies and startups keep coming. "We’re seeing just a ton of new entrepreneurs coming out of graduate and undergraduate programs and starting companies.” John is the founder and CEO of SynBioBeta which takes place May 6-9th in the San Jose Convention Center. 

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Synthetic Biology in 2024 with John Cumbers

Most of the news coming from Illumina has had to do with their leadership in the sequencing instrument space. What is lesser known is that they offer an end-to-end solution for the clinical lab, including variant calling and genome interpretation.In this podcast, we’re joined by Sam Strom, Principal Scientist at Illumina and a certified Clinical Lab Director.  Sam comes to Illumina from the clinical testing side; for example, he’s co-chair for the expert curation panel for Parkinson’s Disease and sits on a working group at ClinGen.In the interview, Sam addresses two of the big challenges in clinical sequencing, which are variant calling and variant interpretation. Sam says Illumina has created its own multi-sample genomic reference and is also making use of artificial intelligence to improve variant calling. He also shares how Illumina supports scaling variant interpretation for genomes and other assays with an AI and automation comprehensive solution, enabling high-quality genetic testing workflows to reach next level accessibility.“I think we’re going to see more “lights out” testing where there really isn’t an interpretation component to the test.   It’s a pure technical test.  It has certain limitations.  But it gets you 99.9% of the way there.  The technology is ready." 

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Illumina Scales Variant Calling and Genome Interpretation to Improve Gap in Genetic Testing with Sam Strom

This is a free preview of a paid episode. To hear more, visit www.mendelspod.com

Today, we feature a new DNA synthesis company out of Sweden that is making a name with long, single-stranded DNA at scale. How long? Over 10,000 bases. Why single-stranded vs. genes? And what is meant by scale?According to Cosimo Ducani, CEO and co-founder of Moligo Technologies, the business of making DNA is just getting started.  So much for thinking it was a mature business in the early 2000s when Integrated DNA Technologies (IDT) dominated the market.

The Renaissance in DNA Synthesis Continues: Cosimo Ducani, CEO, Moligo

The rise of RNA therapeutics and cell therapies promises to take us where we’ve never been in medicine.  The growing understanding of RNA, mRNA, and circular RNA and their crucial roles in disease has led to their application in targeting previously “undruggable” targets.  Meanwhile, new cell therapies are promising cures to diseases that have plagued us without mercy.  Scientists now ask what can’t we do.  Still, biology remains dauntingly complex.At the base of these fields is a revolution in biological engineering. One company stands out with the impressive vision of making engineering biology easier: Boston-based Ginkgo Bioworks. This past month, Ginkgo announced that it was buying three companies to boost its AI footprint in diagnostics and therapeutics. We think of burgers and perfumes, but Ginkgo’s customer base is impressively diverse. Today, we talk with Jennifer Wipf, Head of Commercial Cell Engineering at Ginkgo. Jennifer says FNA is giving drug developers “access to the cell” which is opening up a whole new approach to therapeutics.    How does Ginkgo help out?  What are the promises and challenges?We end with a question about Ginkgo’s new acquisitions to beef up its AI capabilities after last year's partnership with Google.“If  you want to make biology easier to engineer, we need a way to answer some of these questions without doing a lot of lab work."  

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe

Lisa Alderson on Her Telegenetics Firm, Genome Medical, Also Speaks to the DTC Downturn

Download our free app to listen on your phone